Chi Siamo

Le persone

La Governance di Pri.Banks è costituita dal Consiglio generale e dal Comitato, composti dai rappresentanti di ciascun associato, scelti fra coloro che fanno parte del Consiglio di Amministrazione o della Direzione generale.

Elenco Consiglieri

Presidente

Pietro Sella

Gruppo Sella

Presidente onorario

Camillo Venesio

Banca del Piemonte

Vice presidenti

Francesco Passadore

Banca Passadore

Giovanni Pirovano

Banca Mediolanum

Consiglio generale

Erica Azzoaglio

Banco di Credito P. Azzoaglio

Raffaele Basile

Imprebanca

Massimiliano Belingheri

BFF Bank

Giovanni Bossi

Cherry Bank

-

Banca Profilo

Paolo Caroli

Banca Privata Leasing

Ferdinando Cavallini

Banca Macerata

Iacopo De Francisco

Banca CF+

Alessandro Decio

Banco Desio

Frank Fogiel

Solution Bank

Ernesto Fürstenberg Fassio

Banca Ifis

Gianluca Garbi

Banca Sistema

Fabio Innocenzi

Banca Finint

Massimo Luviè

Banca Reale

Francesco Maiolini

Banca del Fucino

Franco Masera

IBL Banca

Peter Mayr

Südtirol Bank

Stefano Morellini

Credito Emiliano

Arturo Nattino

Banca Finnat

Lorena Pelliciari

FinecoBank

Josef Prader

Prader Bank

Andrea Ragaini

Banca Generali

Guido Rosa

A.I.B.E.

Andrea Rotti

ERSEL Banca Privata S.p.A.

Mario Ruta

Allianz Bank Financial Advisors

Maurizio Santoro

Banca Stabiese

Germano Turinetto

ViViBanca

Paolo Vistalli

Cassa Lombarda

Membri del Comitato

Revisori

Presidente

Simone Azzoaglio

Banco di Credito P. Azzoaglio

Membro effettivo

Gerardo Rubinato

A.I.B.E.

Membro effettivo

Federico Villa

Banca Mediolanum

Direttore generale

Emanuele Mario Parisi

Governance

David Kahn

Chief Executive Officer

E: d.kahn@stem-bio.tech

P: +614 4389 2001

Victoria Ruiz

Chief Financial Officer

E: v.ruiz@stem-bio.tech

P: +614 4389 2015

Agents

Luke Connors

Head of Product

E: l.connors@stem-bio.tech

P: +614 4389 2147

Caitlyn Kirby

Product Manager

E: c.kirby@stem-bio.tech

P: +614 4389 2152

Graham Vioski

Head of Development

E: g.vioski@stem-bio.tech

P: +614 4389 2163

Bella Ridley

Key Accounts Manager

E: b.ridley@stem-bio.tech

P: +614 4389 2165

Our Process

01

Discovery and Assessment

The journey begins with proactive search for promising medical research projects. Our team conducts a thorough assessment, evaluating each project's innovation, potential impact, and feasibility. This involves rigorous scientific review, potential market analysis, and preliminary discussions with research teams to understand their vision, capabilities, and needs.

02

Due Diligence and Selection

Following initial assessments, selected projects undergo a comprehensive due diligence process. This step digs deeper into the project's technical details, team qualifications, legal considerations, and financial requirements. It ensures that only the most viable and impactful projects are chosen for funding, aligning with Stem's mission to accelerate the development of transformative healthcare solutions.

03

Matching with Investors

Once a project passes our stringent evaluation process, Stem matches it with suitable investors from our network. This matchmaking is based on the project's specific needs and the investor's interest areas and investment philosophy. Our aim is to create synergistic partnerships that provide not just financial support but also strategic value to propel the research forward.